Profile (CV) of the research teaching staff

Pardo Jimeno, Julián
Department: Departamento de Microbiología, Pediatría, Radiología y Salud Pública
Field: Inmunología
Faculty: Facultad de Medicina

Research Institute: INSTITUTO INVESTIGACIÓN SANITARIA DE ARAGÓN (IIS)

Number of 6-year periods of research productivity evaluation
  • CNEAI research evaluation. 01/01/24
  • CNEAI research evaluation. 25/05/22. (3)
  • ARAID. 04/06/17
  • ARAID. 04/06/12. (2)
Academic position: Cated. Universidad

Academic position
  • Director de División Biomédica del Servicio General de Apoyo a la Investigación
ORCID number: 0000-0003-0154-0730

University degrees
  • Licenciado en Ciencias Químicas Especialidad Química Orgánica. Universidad de Zaragoza. 1999

PhDs
  • Doctor en Programa Oficial de Posgrado en Bioquímica y biología molecular. Universidad de Zaragoza. 2003

Download curriculum in PDF format Download full CVNGo to ORCID page

 
                 
With over 25 years of experience in biomedical research, I have collaborated with interdisciplinary teams—including academia, clinical researchers, and industry—in the fields of immunology, cancer immunotherapy, inflammation, and infection, with a special focus on T-lymphocyte and NK-cell-specific cellular immunity. I lead the Immunotherapy, Inflammation & Cancer research group at IISA as well as a group at CIBERINFECT. I have participated as Principal Investigator in multiple national and European projects (total 26, 11  as PI), securing over €6 million in total funding, in addition to 10 R&D contracts—all led as PI—with a combined total of €3 million.çAmong my achievements, my laboratory was the first to describe the role of granzymes in cancer, specifically Tc-lymphocyte-induced apoptosis via granzymes, and the role of gzmA in arthritis, sepsis, and inflammatory colorectal cancer. The significance of our findings is underscored by invitations to write review articles in high-impact journals such as Trends in Cancer (2018 and 2020) and Nature Reviews Rheumatology (2024).
Currently, we are investigating gzmA-mediated inflammation in observational studies covering sepsis, influenza, and COVID-19. I have also contributed to the scientific leadership of a Phase I/II clinical trial of a new FasL blocker in COVID-19 (NCT04535674), designed in collaboration with clinical investigators and industry, illustrating the translational relevance of our research.
I coordinate a WP on CAR-T cell development within the ERC-Advanced ICOMICS project and the ERC-Proof of Concept VASTO project, which examines the mechanical role of the tumor microenvironment in CAR-T efficacy against solid tumors—led by J.¿M. García Aznar.
I have published over 130 articles in high-impact international journals including Nature Immunology, Immunity, Journal of Infectious Diseases, Journal of Cell Biology, JITC, Science Advances, Angewandte Chemie, Blood, Cell Reports, and Cell Death & Differentiation. These publications have been cited more than 7,000 times, with an h-index of 38 (36 excluding self-citations). Thirty of these papers have received over 50 citations each by prominent researchers in the field—for example: Clinical Cancer Research (2015) – 462 citations. ACS Nano (2015) – 320 citations. Immunity (2008) – 280 citations. Journal of Cell Biology (2004) – 114 citations.Cell Death & Differentiation (2007) – 108 citations. Eukaryotic Cell (2007) – 189 citations. Cell Reports (2014) – 53 citations. JITC (2020) – 40 citations- Trends in Cancer (2020) – 106 citations. These findings have led to multiple patents, highlighting their high relevance to the field. I have supervised 20 doctoral theses, delivered invited talks at national and international conferences, and participated in numerous public outreach activities in collaboration with organizations such as AECC, ASPANOA, and FARO.
We have established various industry collaborations (Certest, Solutex, BDR, World Pathol, IBIAN, BMS, NovaPan, etc.) via R&D contracts. I am a co-inventor on six patents related to infection diagnostics and immunotherapy in infectious diseases and cancer—one of which has been licensed to BDR.
Thanks to my experience and achievements, I was appointed coordinator of the new Advanced Therapies Unit at Miguel Servet Hospital in Zaragoza. I have taught Immunology at the University of Zaragoza for the past 12 years, and in September 2024 I became a Full Professor in this field.

© University of Zaragoza | Versión 2.28.0
© Computing and Communications Service of the University of Zaragoza (Pedro Cerbuna 12, 50009 ZARAGOZA - SPAIN)